Last reviewed · How we verify
Mulpleta (LUSUTROMBOPAG)
Mulpleta (generic name: LUSUTROMBOPAG) is a Small molecule drug developed by Vancocin Italia. It is currently FDA-approved (first approved 2018) for Thrombocytopenic disorder.
Mulpleta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow.
Mulpleta is a small molecule that acts as a thrombopoietin receptor agonist. It is used to treat conditions such as thrombocytopenia, immune thrombocytopenia (ITP), and thrombocytopenia in patients with chronic liver disease.
At a glance
| Generic name | LUSUTROMBOPAG |
|---|---|
| Sponsor | Vancocin Italia |
| Target | Thrombopoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2018 |
Mechanism of action
Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
Approved indications
- Thrombocytopenic disorder
Common side effects
- Headache
- Portal vein thrombosis
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation (NA)
- Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) (PHASE2)
- Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery (PHASE2)
- A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag (PHASE4)
- Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE4)
- A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) (PHASE2)
- An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP) (PHASE2)
- Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mulpleta CI brief — competitive landscape report
- Mulpleta updates RSS · CI watch RSS
- Vancocin Italia portfolio CI
Frequently asked questions about Mulpleta
What is Mulpleta?
How does Mulpleta work?
What is Mulpleta used for?
Who makes Mulpleta?
What is the generic name of Mulpleta?
When was Mulpleta approved?
What development phase is Mulpleta in?
What are the side effects of Mulpleta?
What does Mulpleta target?
Related
- Target: All drugs targeting Thrombopoietin receptor
- Manufacturer: Vancocin Italia — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thrombocytopenic disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing